City of Hope broke ground on a new Pathology and Radiation Oncology Building designed to expand cancer treatment capacity and streamline care delivery in Los Angeles County.
The oncology field is confronting three forces simultaneously.
City of Hope breaks ground on facility uniting cancer diagnosis and treatment
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
Top HHS officials last week called for a “moonshot” focused on the role of the microbiome in cancer.
For years, clues pointed to the gut microbiome as a key factor in cancer treatment outcomes. Recent advances in gene sequencing are now clarifying its influence on how patients respond to therapy.
A profile of Steven T. Rosen aired on Spectrum News 1 “California Stories with Giselle Fernandez” on May 11.
Quest Diagnostics, a provider of diagnostic information services, announced that City of Hope is implementing Haystack MRD, a circulating-tumor DNA minimal residual disease test, for clinical trial participants with solid tumor cancers to help guide disease management for patients being treated for breast, colorectal, ovarian, and prostate cancer.
The era of genomic oncology is defined by complexity. Over the last decades, we have moved from single-gene tests to multi-gene panels and, eventually, will be routinely using whole-exome/whole-genome and transcriptome sequencing in clinical care.
